[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"direct-oral-anticoagulant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:direct-oral-anticoagulant":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,54],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100606247","evaluation-of-the-relationship-between-muscle-mass-measured-by-bioelectrical-impedance-analysis-and-the-risk-of-hemorrhagic-events-under-direct-oral-anticoagulants-in-the-elderly-100606247",false,"NCT07173075","Evaluation of the Relationship Between Muscle Mass Measured by Bioelectrical Impedance Analysis and the Risk of Hemorrhagic Events Under Direct Oral Anticoagulants in the Elderly","SARCORRHAGED","Inclusion Criteria:\n\n* age of at least 70 years\n* treated with one of the two factor Xa inhibitors used in France: Apixaban, Rivaroxaban.\n* For cases : hemorrhagic event causing hospitalization\n* For controls : free from hemorrhagic events.\n\nExclusion Criteria:\n\n* Failure to obtain a consent form\n* Patient under legal protection (guardianship, curatorship, or legal safeguard)\n* Recurrent bleeding from a pre-existing lesion that has not received specific treatment. For example: unexplored gastrointestinal bleeding, cutaneous bleeding from a cancerous wound with therapeutic abstention.\n* Bleeding caused by high-velocity trauma, surgery, or assault\n* Contraindications to impedance measurement: pacemaker, cardiac defibrillator\n* Elements that may provide erroneous impedance measurement data: bilateral limb amputation, bilateral joint replacements, dialysis.\n* Unable to maintain the supine position.\n* Digestive absorption disorder (celiac disease, short bowel, stoma, etc.)","ALL","70 Years",{"count":19,"type":20},110,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to assess whether reduced muscle mass is associated with an increased risk of bleeding in the elderly receiving direct oral anticoagulant therapy.\n\nThe researchers will compare the muscle mass of patients who experienced a hemorrhage (case) with that of patients who did not (control).\n\nMuscle mass is a key criterion in the assessment of sarcopenia and malnutrition, two conditions frequently associated with aging. Sarcopenia is characterized by a significant loss of muscle mass and strength, while malnutrition is an alteration of nutritional status, often accompanied by sarcopenia, weight loss or a low body mass index (BMI). So at the same time, we want to compare sarcopenia and malnutrition between the two groups (case and control).\n\nCases and controls will benefit from a consultation during which measurements will be taken: weight, height, BMI, calf circumference, impedancemetry, etc. A blood test will be taken to measure anti-Xa activity (drug activity) and any missing analyses.",[26,27,28,29,30,31],"Direct Oral Anticoagulant","Hemmorhage","Elderly","Muscle Mass","Sarcopenia","Denutrition",[33,34,35,36,37,38,39,40],"direct oral anticoagulant","hemmorhage","bleeding","elderly","muscle mass","sarcopenia","denutrition","impedancemetry","NOT_YET_RECRUITING","2025-09-12",{"date":44,"type":45},"2025-09-15","ACTUAL",{"date":47,"type":20},"2025-10",{"date":49,"type":20},"2027-10",{"name":51,"class":52},"University Hospital, Clermont-Ferrand","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":21,"phases":64,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":53},"100584279","peri-procedural-management-of-direct-oral-anticoagulants-for-central-venous-catheters-in-cancer-patients-with-venous-thromboembolism-or-atrial-fibrillation-pilot-study-100584279","NCT06887270","Peri-procedural Management of Direct Oral Anticoagulants for Central VENOus Catheters in CAncer Patients With Venous Thromboembolism or Atrial Fibrillation Pilot Study","Peri-procedural Management of Direct Oral Anticoagulants for Central VENOus Catheters in CAncer Patients With Venous Thromboembolism or Atrial Fibrillation (VENOCAT) Pilot Study","VENO CAT","Inclusion Criteria:\n\n1. Adult patients with VTE or non-valvular AF on prophylactic or therapeutic dose DOAC\n2. Active cancer, defined as diagnosed within the past 6 months; or recurrent, regionally advanced, or metastatic cancer; or for which treatment had been administered within 6 months of port or tunneled CVC insertion; or hematologic cancer not in complete remission\n3. Pending elective radiologically guided insertion of tunneled or port CVC\n4. Able and willing to adhere to peri-procedural DOAC management plan and follow-up\n\nExclusion Criteria:\n\n1. Creatinine clearance (Cockcroft-Gault equation) \\\u003C30 mL\u002Fmin for Dabigatran, Rivaroxaban, or Edoxaban, and \\\u003C25mL\u002Fmin for Apixaban\n2. Diagnosis of VTE within 21 days\n3. Platelet count \\\u003C 50 x 10\\^9\u002FL at time of study entry\n4. Concomitant strong inhibitors or inducers to P-glycoprotein and\u002For CYP-3A4",{"count":63,"type":20},10,[23],"The peri-procedural management of direct oral anticoagulants (DOACs) in persons with cancer (PWC) undergoing tunneled or port central venous catheter (CVC) insertion is a common but understudied clinical problem, with conflicting management advice from guidelines and resultant uncertainty for best practices. Data from prospective studies assessing peri-procedural DOAC management exist; however, these data pertain to procedures in the general population. These management strategies may not be applicable to PWC because (1) although CVC insertion is a low risk, image-guided specialized procedure, (2) PWC are at considerably higher risk of peri-procedural bleeding and thrombosis than non-PWC. It is not surprising, therefore, that guideline recommendations and current practices vary widely. To resolve management uncertainty and establish a standard-of-care, the VENOCAT pilot randomized controlled trial (RCT) is a first step that will assess the feasibility of a definitive trial comparing continued vs. interrupted DOAC management in PWC undergoing tunneled or port CVC insertion. Evidence is needed to standardize clinical practice and reduce the risk of bleeding and thrombotic complications.",[67,26,68,69,70],"Anticoagulant-induced Bleeding","Cancer","Central Venous Catheter","Periprocedural Complication","2025-03-13",{"date":73,"type":45},"2025-03-20",{"date":75,"type":20},"2025-09",{"date":77,"type":20},"2027-09",{"name":79,"class":52},"University Health Network, Toronto"]